Neurocrine amends 8-K to update pro forma financials for Soleno acquisition

Neurocrine filed an amended current report to update unaudited pro forma financials tied to its Soleno acquisition, which closed May 18, 2026.

The amendment presents pro forma combined results as if the deal closed on Jan. 1, 2025, including updated purchase accounting adjustments.

• Pro forma net income totaled $294 million for the six months ended June 30, 2026, with basic EPS of $2.92.
• Pro forma net income was $324.5 million for 2025, with basic EPS of $3.26.
• The company repaid a $600 million revolver draw by June 30, 2026, with no pro forma adjustments recorded for the borrowing.